Clinical trial · Observational
Integrated Cancer Repository for Cancer Research
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The iCaRe2 is a multi-institutional resource created and maintained by the Fred \& Pamela Buffett Cancer Center to collect and manage standardized, multi-dimensional, longitudinal data and biospecimens on consented adult cancer patients, high-risk individuals, and normal controls. The distinct characteristic of the iCaRe2 is its geographical coverage, with a significant percentage of small and rural hospitals and cancer centers. The iCaRe2 advances comprehensive studies of risk factors of cancer development and progression and enables the design of novel strategies for prevention, screening, early detection and personalized treatment of cancer. Centers with expertise in cancer epidemiology, genetics, biology, early detection, and patient care can collaborate by using the iCaRe2 as a platform for cohort and population studies.
Conditions
Conditions (50)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anal Cancer | Malignant Anal Neoplasm | CURATED_EXACT | 0.92 |
| Bile Duct Cancer | Malignant Bile Duct Neoplasm | CURATED_BROADER | 0.80 |
| Bladder Cancer | Malignant Bladder Neoplasm | CURATED_EXACT | 0.92 |
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Central Nervous System Cancer | Malignant Central Nervous System Neoplasm | ALIAS | 0.90 |
| Central Nervous System Tumor | Central Nervous System Neoplasm | ALIAS | 0.90 |
| Colon Cancer | Malignant Colon Neoplasm | CURATED_EXACT | 0.92 |
| Duodenal Cancer | Malignant Duodenal Neoplasm |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Development and Implementation of a Web-based Cancer Collaborative Registry
- timeFrame
- 86 years
- description
- This is a registry that will continue to accrue participants indefinitely.
Secondary outcomes (1)
- measure
- Procurement and Banking of Excess Biological Material for Future Analysis
- timeFrame
- 86 years
- description
- This is a registry that will continue to accrue participants indefinitely.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 19 Years
- Maximum age
- 110 Years
Show eligibility criteria text
Inclusion Criteria * Diagnosis/history of cancer * Risk for developing cancer or suspicious clinical findings * No history of cancer (normal control registry) * Able to provide informed consent * 19 years of age or older * English or Spanish speaking individuals Exclusion Criteria * Unable to provide informed consent because of cognitive impairment * Non-English or non-Spanish speaking individuals
References
Publications (0)
Data not yet available